ClinicalTrials.gg
CompletedNCT06978322Updated Oct 16, 2026

Comparative Study Between Immediate Surgery Versus Neoadjuvant Chemotherapy for Management of Resectable Pancreatic Cancer

An observational study in Surgery, Neoadjuvant Chemotherapy and Management, sponsored by Minia University. Completed at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Minia University · Observational

How we know

Updated Oct 16, 2026Enrollment updatedStart date moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
81
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Pancreatic Neoplasms by Minia University — 11 open to participants now, 11 under way, 1 of them phase 3. Pancreatic Neoplasms · Minia University.

Started
2022
the only one that year
Observational
3 of 13
1 open now
Registered
2nd of 13
by date

Among the 13 studies in Pancreatic Neoplasms by Minia University, this one is the only one that started in 2022, is one of 3 observational ones, and was the 2nd registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

11 of the 13 studies in Pancreatic Neoplasms by Minia University are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Pancreatic Neoplasms by Minia University, or all of them as a file.
02

Study summary

This trial aimed to determine whether neoadjuvant chemoradiotherapy improves overall survival compared with upfront surgery, both followed by adjuvant chemotherapy in patients with resectable and borderline resectable pancreatic cancer.

Read the detailed description

Pancreatic cancer is one of the solid cancers with the poorest treatment outcomes, and there is an urgent need to improve its treatment outcomes. Among these, resectable pancreatic cancer is known to show relatively good treatment outcomes with surgical resection, but the 5-year survival rate is still about 20%, which is still unsatisfactory.

Neoadjuvant therapy may increase the proportion of patients that actually receive chemotherapy and thereby improve survival. Furthermore, neoadjuvant therapy may increase the microscopically margin-negative (R0) resection rate and may identify patients with rapidly progressive disease who can be spared futile surgery.

03

Conditions studied

  • Surgery
  • Neoadjuvant Chemotherapy
  • Management
  • Resectable Pancreatic Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This prospective and retrospective study will be conducted on 30 patients with resectable pancreatic cancer.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Computed tomography (CT) with pancreatic protocol + vascular mapping
  • Histopathologically proven malignant by CT-guided or endoscopic ultrasound (EUS)-guided Resectable pancreatic cancer means no contact of the tumor with the Superior mesenteric artery, Celiac axis \& Common hepatic artery, and contact of the tumor but ≤90° contact with the superior mesenteric vein \& portal vein.

Exclusion criteria

Exclusion Criteria:

  • Borderline resectable \& locally advanced pancreatic cancer
  • Tumor at the tail of the pancreas.
  • pancreatic cancer
  • Unfit patients for surgery.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
81 participants (actual)
Patient registry
No

Groups and cohorts

  • Immediate surgery group

    Patients will undergo upfront surgery, then adjuvant chemotherapy.

    Procedure: Immediate surgery

  • Neoadjuvant chemotherapy group

    Patients will undergo neoadjuvant chemotherapy, then surgery.

    Procedure: Neoadjuvant chemotherapy

Interventions

  • ProcedureImmediate surgery

    Patients will undergo upfront surgery, then adjuvant chemotherapy.

  • ProcedureNeoadjuvant chemotherapy

    Patients will undergo neoadjuvant chemotherapy, then surgery.

06

What researchers measure

Primary outcomes

  1. Overall survival rate

    Overall survival will be measured as the time between date of randomization and date of death from any cause or date of last follow-up if alive.

    Time frame: 1 year post-procedure

Secondary outcomes

  1. Achieve of R0 Resection

    Resection is defined as the number of patients with an R0 resection margin. R0 resection margin rate will be measured according to the Africa Regional Collaborative Platform (RCP) report on standards and datasets for reporting cancers.

    Time frame: 1 year post-procedure

  2. Disease free survival

    Disease-free survival will be measured as the time between date of surgery and date of disease recurrence.

    Time frame: 1 year post-procedure

  3. Time to locoregional recurrence

    Time to locoregional recurrence will be recorded.

    Time frame: 1 year post-procedure

  4. Time to distant metastasis

    Time to distant metastasis will be recorded.

    Time frame: 1 year post-procedure

  5. Incidence of postoperative complications

    Incidence of postoperative complications such as hemorrhage and pancreatic fistula will be recorded.

    Time frame: 1 year post-procedure

07

Study locations

1 site
  • Minia University
    Minya, Minya Governorate 61611, Egypt
08

References and documents

Individual participant data

Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

Supporting information: Study protocol

Time frame: After the end of study for one year.

Access criteria: The data will be available upon a reasonable request from the corresponding author.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Feb 2022 to primary completion in Feb 2025, 36 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: start Feb 2025 → Feb 2022, primary completion Feb 2026 → Feb 2025 and completion Feb 2026 → Oct 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2025
First posted
May 18, 2025
StartActual
Feb 1, 2022was Feb 2025
Primary completionActual
Feb 1, 2025was Feb 2026
CompletionActual
Oct 1, 2025was Feb 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Feb 1, 2025→Feb 1, 2022
Oct 8, 2026
Primary completion
Feb 1, 2026→Feb 1, 2025
Oct 8, 2026
Study completion
Feb 1, 2026→Oct 1, 2025
Oct 8, 2026
Enrollment
50→81
Oct 16, 2026
Show all 2 updates
  1. Oct 16, 2026
    Enrollment 50→81
  2. Oct 8, 2026
    Start date Feb 1, 2025→Feb 1, 2022
    Primary completion Feb 1, 2026→Feb 1, 2025
    Study completion Feb 1, 2026→Oct 1, 2025
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06978322
Lead sponsor
Minia University
Responsible party
Abdelrahman Mohamed Salah (Lecturer of General Surgery, Faculty of Medicine, Minia University, Minia, Egypt., Minia University) — Principal investigator
First posted
May 18, 2025
Start date
Feb 1, 2022
Primary completion
Feb 1, 2025
Completion
Oct 1, 2025
Last update
Oct 16, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion